Cargando…

Hyperglycemia Risk Evaluation of Hydrocortisone Intermittent Boluses vs Continuous Infusion in Septic Shock: A Retrospective Study

INTRODUCTION: Hydrocortisone showed to be effective in reducing the time until reversal of shock when added to standard therapy in managing septic shock. Hyperglycemia is one of the common adverse effects associated with corticosteroid treatment. However, the difference in hyperglycemia risk with di...

Descripción completa

Detalles Bibliográficos
Autores principales: Mitwally, Hassan, Saad, Mohamed O, Mahmoud, Sara, Mohamed, Adham
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Jaypee Brothers Medical Publishers 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7874298/
https://www.ncbi.nlm.nih.gov/pubmed/33603298
http://dx.doi.org/10.5005/jp-journals-10071-23501
_version_ 1783649565031792640
author Mitwally, Hassan
Saad, Mohamed O
Mahmoud, Sara
Mohamed, Adham
author_facet Mitwally, Hassan
Saad, Mohamed O
Mahmoud, Sara
Mohamed, Adham
author_sort Mitwally, Hassan
collection PubMed
description INTRODUCTION: Hydrocortisone showed to be effective in reducing the time until reversal of shock when added to standard therapy in managing septic shock. Hyperglycemia is one of the common adverse effects associated with corticosteroid treatment. However, the difference in hyperglycemia risk with different methods of hydrocortisone administration is not clear. The objective of this study was to evaluate the risk of hyperglycemia of intermittent hydrocortisone boluses vs continuous infusion in septic shock patients. MATERIALS AND METHODS: This was a retrospective observational study. Data were collected from the electronic medical records of eligible patients admitted to intensive care units. All patients admitted with septic shock who received noradrenaline and hydrocortisone were included. Only patients who exceeded 200 mg/day of hydrocortisone were excluded. The primary outcome was mean blood glucose. RESULTS: A total of 108 patients (with 3,021 blood glucose readings) were included in the final analysis. Seventy-six patients received hydrocortisone as intermittent boluses (70.3%), and 32 patients (29.7%) received continuous infusion. For the primary outcome, no statistically or clinically significant difference was found in the blood glucose estimated marginal mean: 8.58 mmol/L (95% confidence interval [CI]; 8.01–9.16) in the bolus group and 8.9 mmol/L (95% CI; 7.99–9.82) in the infusion group with a mean difference of 0.32 mmol/L (95% CI; −0.77 to 1.41). For secondary outcomes, no difference was found between the two groups in mortality, length of stay, reversal of shock, or hypoglycemic events. CONCLUSION: Intermittent boluses of hydrocortisone were not associated with a higher risk of hyperglycemia than continuous infusion in septic shock patients. HOW TO CITE THIS ARTICLE: Mitwally H, Saad MO, Mahmoud S, Mohamed A. Hyperglycemia Risk Evaluation of Hydrocortisone Intermittent Boluses vs Continuous Infusion in Septic Shock: A Retrospective Study. Indian J Crit Care Med 2021;25(1):29–33.
format Online
Article
Text
id pubmed-7874298
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Jaypee Brothers Medical Publishers
record_format MEDLINE/PubMed
spelling pubmed-78742982021-02-17 Hyperglycemia Risk Evaluation of Hydrocortisone Intermittent Boluses vs Continuous Infusion in Septic Shock: A Retrospective Study Mitwally, Hassan Saad, Mohamed O Mahmoud, Sara Mohamed, Adham Indian J Crit Care Med Research Article INTRODUCTION: Hydrocortisone showed to be effective in reducing the time until reversal of shock when added to standard therapy in managing septic shock. Hyperglycemia is one of the common adverse effects associated with corticosteroid treatment. However, the difference in hyperglycemia risk with different methods of hydrocortisone administration is not clear. The objective of this study was to evaluate the risk of hyperglycemia of intermittent hydrocortisone boluses vs continuous infusion in septic shock patients. MATERIALS AND METHODS: This was a retrospective observational study. Data were collected from the electronic medical records of eligible patients admitted to intensive care units. All patients admitted with septic shock who received noradrenaline and hydrocortisone were included. Only patients who exceeded 200 mg/day of hydrocortisone were excluded. The primary outcome was mean blood glucose. RESULTS: A total of 108 patients (with 3,021 blood glucose readings) were included in the final analysis. Seventy-six patients received hydrocortisone as intermittent boluses (70.3%), and 32 patients (29.7%) received continuous infusion. For the primary outcome, no statistically or clinically significant difference was found in the blood glucose estimated marginal mean: 8.58 mmol/L (95% confidence interval [CI]; 8.01–9.16) in the bolus group and 8.9 mmol/L (95% CI; 7.99–9.82) in the infusion group with a mean difference of 0.32 mmol/L (95% CI; −0.77 to 1.41). For secondary outcomes, no difference was found between the two groups in mortality, length of stay, reversal of shock, or hypoglycemic events. CONCLUSION: Intermittent boluses of hydrocortisone were not associated with a higher risk of hyperglycemia than continuous infusion in septic shock patients. HOW TO CITE THIS ARTICLE: Mitwally H, Saad MO, Mahmoud S, Mohamed A. Hyperglycemia Risk Evaluation of Hydrocortisone Intermittent Boluses vs Continuous Infusion in Septic Shock: A Retrospective Study. Indian J Crit Care Med 2021;25(1):29–33. Jaypee Brothers Medical Publishers 2021-01 /pmc/articles/PMC7874298/ /pubmed/33603298 http://dx.doi.org/10.5005/jp-journals-10071-23501 Text en Copyright © 2021; Jaypee Brothers Medical Publishers (P) Ltd. © Jaypee Brothers Medical Publishers. 2021 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted use, distribution, and non-commercial reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Mitwally, Hassan
Saad, Mohamed O
Mahmoud, Sara
Mohamed, Adham
Hyperglycemia Risk Evaluation of Hydrocortisone Intermittent Boluses vs Continuous Infusion in Septic Shock: A Retrospective Study
title Hyperglycemia Risk Evaluation of Hydrocortisone Intermittent Boluses vs Continuous Infusion in Septic Shock: A Retrospective Study
title_full Hyperglycemia Risk Evaluation of Hydrocortisone Intermittent Boluses vs Continuous Infusion in Septic Shock: A Retrospective Study
title_fullStr Hyperglycemia Risk Evaluation of Hydrocortisone Intermittent Boluses vs Continuous Infusion in Septic Shock: A Retrospective Study
title_full_unstemmed Hyperglycemia Risk Evaluation of Hydrocortisone Intermittent Boluses vs Continuous Infusion in Septic Shock: A Retrospective Study
title_short Hyperglycemia Risk Evaluation of Hydrocortisone Intermittent Boluses vs Continuous Infusion in Septic Shock: A Retrospective Study
title_sort hyperglycemia risk evaluation of hydrocortisone intermittent boluses vs continuous infusion in septic shock: a retrospective study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7874298/
https://www.ncbi.nlm.nih.gov/pubmed/33603298
http://dx.doi.org/10.5005/jp-journals-10071-23501
work_keys_str_mv AT mitwallyhassan hyperglycemiariskevaluationofhydrocortisoneintermittentbolusesvscontinuousinfusioninsepticshockaretrospectivestudy
AT saadmohamedo hyperglycemiariskevaluationofhydrocortisoneintermittentbolusesvscontinuousinfusioninsepticshockaretrospectivestudy
AT mahmoudsara hyperglycemiariskevaluationofhydrocortisoneintermittentbolusesvscontinuousinfusioninsepticshockaretrospectivestudy
AT mohamedadham hyperglycemiariskevaluationofhydrocortisoneintermittentbolusesvscontinuousinfusioninsepticshockaretrospectivestudy